Exicure Shares Surge 63.8% After $5.6M Settlement Motion and SEC Filings

EXICURE INC (XCUR)

EXICURE INC (ticker: XCUR; Korean name: 엑시큐어) is a clinical-stage biotechnology company headquartered in Chicago, Illinois, focused on developing nucleic acid therapies. Its proprietary Spherical Nucleic Acid (SNA) platform targets disease-relevant RNA in indications related to neurology, immuno-oncology, inflammatory disorders, and genetic diseases.

Ticker	Exchange	Price (2025-12-09)	Change (%)	Volume
XCUR	NAS	$8.73	+63.79%	3,867,501

Corporate Structure and Expertise

Exicure operates from a 30,000 sq ft in-house facility equipped for rapid, automated high-throughput nucleic acid synthesis and screening. Since its founding in 2011, the company has assembled a team of fewer than 50 employees with expertise in:

• Oligonucleotide chemistry
• Drug development
• Neuroscience

This multidisciplinary group conducts discovery and development efforts internally, advancing candidates from target validation to in vivo proof-of-concept studies.

Nucleic acid therapy by charlesdeluvio

Developments and News

• On September 6, 2024, Bleichmar Fonti & Auld LLP filed a motion for preliminary approval of a $5.625 million class settlement in securities litigation alleging prior misstatements concerning XCUR-FXN drug data. The proposed fund would cover purchases of Exicure common stock during the period from January 7, 2021, to December 10, 2021.

• The Form 10-Q for the quarter ended September 30, 2025, filed on November 7, 2025, highlights Exicure’s ongoing investment in research and development. For detailed financial results, stakeholders are encouraged to consult the full filing.

• Two Form 8-K filings (November 10 and November 17, 2025) report material events under items 5.07, 8.01, and 9.01. Stakeholders are directed to the SEC links for more information.

• Trading activity on December 8, 2025, resulted in an increase in the share price to $8.73, corresponding to a 63.79% gain on a trading volume exceeding 3.8 million shares.

Financial and Strategic Analysis

As of November 2025, key financial metrics include:

• Market capitalization: approximately $33.7 million
• Total cash: $4.44 million
• Total debt/equity ratio: 5.28%
• Trailing twelve-month net loss: $9.23 million (EPS: –3.72)

Exicure has not reported product revenue to date. The company’s strategic focus remains on advancing its pipeline through proof-of-concept studies, with lead programs targeting:

• SCN9A (Nav1.7) non-opioid analgesic
• Neurological conditions including Huntington disease, Angelman syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis

The SNA platform is designed to enhance cellular uptake and stability, which may differentiate Exicure from other oligonucleotide approaches.

Market Position and Industry Context

Exicure operates within the nucleic acid therapy sector, which includes firms utilizing RNA-targeting modalities to tackle diseases with significant unmet needs. Its in-house capabilities and proprietary SNA chemistry place it alongside small biotechnology companies that are progressing toward clinical proof-of-concept. Key challenges in the industry encompass:

• Navigating regulatory approval pathways for novel nucleic acid modalities
• Securing partnerships or additional funding to facilitate late-stage development
• Demonstrating safety and efficacy in human trials

Collaborations with larger pharmaceutical partners or strategic investors could be critical for commercial viability.

tl;dr

EXICURE INC shares rose 63.79% to $8.73 on December 8, 2025, with trading volume of 3.9 million shares. A motion for a $5.625 million class settlement was filed on September 6, 2024. Recent SEC Form 8-K filings on November 10 and 17, 2025, report material developments. Exicure has reported no revenue to date, with a cash position of $4.44 million supporting ongoing R&D. Key assets include an SNA platform and lead programs in neurology. Future developments will depend on clinical data readouts and potential partnerships.